Literature DB >> 23415597

The diagnostic utility of anterior chamber paracentesis with polymerase chain reaction in anterior uveitis.

Zane Anwar1, Anat Galor, Thomas A Albini, Darlene Miller, Victor Perez, Janet L Davis.   

Abstract

PURPOSE: To determine the value of anterior chamber paracentesis with polymerase chain reaction (PCR) in patients with anterior uveitis.
DESIGN: Retrospective observational case series.
SETTING: Bascom Palmer Eye Institute. PATIENT POPULATION: Fifty-three patients with a diagnosis of anterior uveitis who underwent anterior chamber paracentesis with PCR. OBSERVATION PROCEDURES: Anterior chamber paracentesis with PCR of aqueous fluid. MAIN OUTCOME MEASURE: Diagnostic utility and frequency of management change based on anterior chamber paracentesis and PCR.
RESULTS: There were 15 of 53 (28%) acute and 35 of 53 (65%) chronic anterior uveitis patients. PCR positivity of herpes simplex virus, cytomegalovirus, varicella zoster virus, and Epstein-Barr virus in our population were 4 of 53 (8%), 1 of 47 (2%), 1 of 35 (3%), and 1 of 18 (6%). Overall, 7 of 53 patients (13%) had a change in management because of PCR results from anterior chamber paracentesis. Four patients encountered paracentesis complications (4/53, 7.5%), 1 with long-term sequelae.
CONCLUSIONS: Anterior chamber paracentesis with PCR had a relatively low diagnostic utility and resulted in few management changes in patients with suspected infectious anterior uveitis.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23415597     DOI: 10.1016/j.ajo.2012.12.008

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  16 in total

1.  Eighteen months of anterior chamber inflammation.

Authors:  Vishal Jhanji; Rachel Kwok; Alvin L Young
Journal:  BMJ Case Rep       Date:  2013-08-30

2.  A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology.

Authors:  J Michael Miller; Matthew J Binnicker; Sheldon Campbell; Karen C Carroll; Kimberle C Chapin; Peter H Gilligan; Mark D Gonzalez; Robert C Jerris; Sue C Kehl; Robin Patel; Bobbi S Pritt; Sandra S Richter; Barbara Robinson-Dunn; Joseph D Schwartzman; James W Snyder; Sam Telford; Elitza S Theel; Richard B Thomson; Melvin P Weinstein; Joseph D Yao
Journal:  Clin Infect Dis       Date:  2018-08-31       Impact factor: 9.079

3.  Reclassifying Idiopathic Uveitis: Lessons From a Tertiary Uveitis Center.

Authors:  Rene Y Choi; Erick Rivera-Grana; James T Rosenbaum
Journal:  Am J Ophthalmol       Date:  2018-10-22       Impact factor: 5.258

4.  Classification Criteria for Herpes Simplex Virus Anterior Uveitis.

Authors: 
Journal:  Am J Ophthalmol       Date:  2021-04-09       Impact factor: 5.488

5.  Classification Criteria for Varicella Zoster Virus Anterior Uveitis.

Authors: 
Journal:  Am J Ophthalmol       Date:  2021-04-15       Impact factor: 5.488

6.  Classification Criteria for Cytomegalovirus Anterior Uveitis.

Authors: 
Journal:  Am J Ophthalmol       Date:  2021-04-09       Impact factor: 5.488

7.  Classification Criteria for Fuchs Uveitis Syndrome.

Authors: 
Journal:  Am J Ophthalmol       Date:  2021-05-11       Impact factor: 5.488

Review 8.  A Glimpse into Uveitis in the Aging Eye: Pathophysiology, Clinical Presentation and Treatment Considerations.

Authors:  Elizabeth Akinsoji; Raquel Goldhardt; Anat Galor
Journal:  Drugs Aging       Date:  2018-05       Impact factor: 4.271

Review 9.  Current aspects on the management of viral uveitis in immunocompetent individuals.

Authors:  Uwe Pleyer; Soon-Phaik Chee
Journal:  Clin Ophthalmol       Date:  2015-06-05

10.  Aqueous humor polymerase chain reaction in uveitis - utility and safety.

Authors:  Argyrios Chronopoulos; Daniel Roquelaure; Georges Souteyrand; Jörg Dieter Seebach; James Scott Schutz; Gabriele Thumann
Journal:  BMC Ophthalmol       Date:  2016-10-28       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.